Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Longest survival follow-up ever reported for immunotherapy treatment in this setting
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
It is the first autotaxin inhibitor to be investigated in cancer patients
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
Subscribe To Our Newsletter & Stay Updated
